Innovive Pharmaceuticals Inc., of New York, will discontinue development of INNO-105 based on results of a Phase I trial and instead will concentrate resources on the remainder of its oncology pipeline

Bioenvision Inc., of New York, said the latest results from its ongoing European study of Evoltra (clofarabine) in pediatric acute lymphoblastic leukemia patients confirmed that the drug delivers a significant response rate in that population

Inc., of Bothell, Wash., initiated a Phase I pharmacokinetic study to compare its rapid-acting intranasal insulin formulation to compare an approved injectable product to the recently approved inhaled insulin product, Exubera, from New York-based Pfizer Inc

Ortec International Inc., of New York, said a preliminary review of unaudited data from its recently completed confirmatory trial indicates that OrCel healed more venous ulcer wounds and achieved 100 percent wound closure of those wounds sooner than those in the control group

The global Phase III ASSIST trials are designed to compare the efficacy and safety of intravenous iclaprim with that of the market leader linezolid, marketed by Pfizer Inc., of New York, as Zyvox

Vasogen Inc., of Mississauga, Ontario, said new data from the 2,400-patient ACCLAIM trial in chronic heart failure showed that in a major combined subgroup of New York Heart Association Class III/IV patients with no prior history of heart attack and all Class II patients - comprising more than 50 percent of the study population - Vasogen's Celacade technology reduced the risk of death and cardiovascular hospitalization by 31 percent (p=0.0003

Omrix Biopharmaceuticals Inc., of New York, said FFF Enterprises Inc., of Temecula, Calif., will begin a U.S. Phase III open-label, single-arm multicenter trial to treat primary immune deficiency with Omr-IgG-am, the company's intravenous immunoglobulin marketed outside of the U.S. FFF has agreed to take over sponsorship of the active investigational new drug application for Omr-IgG-am in the U.S., and will become the exclusive marketing agent and authorized distributor of the product in the U.S

Amazon Biotech Inc., of New York, signed an interim letter of agreement with the Immunology Clinic of New York to conduct a Phase I/II, randomized, double-blind, placebo-controlled study to test the safety and efficacy of its botanical drug product, AMZ0026, in pre-symptomatic HIV-positive patients undergoing no other anti-retroviral therapies...Innovive Pharmaceuticals Inc., of New York, began a Phase I trial of INNO-406 in patients resistant to Gleevec (imatinib, from Novartis AG) or intolerant

SIGA Technologies Inc., of New York, said its lead smallpox drug candidate, SIGA-246, successfully completed the first planned human safety trial

Keryx Biopharmaceuticals Inc., of New York, disclosed positive final data from a dose-ranging Phase II study with Zerenex, testing the oral, inorganic, iron-based compound's effects on serum phosphate in patients with end-stage renal disease...Manhattan Pharmaceuticals Inc., of New York, began a Phase IIa trial of oral Oleoyl-estrone (OE) for obesity

Callisto Pharmaceuticals Inc., of New York, decided to initiate a single-agent Phase II trial of Atiprimod in advanced carcinoid cancer patients...Omrix Biopharmaceuticals Inc., of New York, said patient enrollment in the multicenter, Phase III trial of the company's Thrombin stand-alone product candidate has been completed

OSI Pharmaceuticals Inc., of Melville, N.Y., and Pfizer Inc., of New York, started a Phase IV trial that will explore the safety and efficacy of Macugen (pegaptanib sodium injection) as a maintenance therapy for patients who have received prior neovascular age-related macular degeneration treatment and experienced improvement in macular disease

Amazon Biotech Inc., of New York, negotiated a Phase I/II protocol with the FDA, allowing the company to start a trial of AMZD026 in HIV patients

Celtic Pharma Holdings LP, of New York, reported preliminary results of two Phase II studies of TA-CD, an immunotherapy vaccine for cocaine addiction, including data from a Phase IIa study in volunteers who reported a substantial reduction in the amount of cocaine used after developing good levels of anti-cocaine antibodies in their blood

Nektar Therapeutics Inc., of San Carlos, Calif., said New York-based Pfizer Inc...N-Gene Research Laboratories Inc., of New York, said Phase II data for BGP-15, an insulin sensitizer, indicated the drug significantly improved insulin sensitivity at both doses tested

Antigenics Inc., of New York, completed an in-depth analysis of its previously reported Phase III trial results of Oncophage (vitespen) vaccine in kidney cancer, which found a 43 percent improvement in recurrence-free survival for a 361-patient subgroup of the study

The trial is being conducted at M.D. Anderson Cancer Center in Houston, with additional patient enrollment expected later this year at Memorial Sloan-Kettering Cancer Center in New York

Axonyx Inc., of New York, completed its second Phase I study with Posiphen to treat Alzheimer's disease progression...Manhattan Pharmaceuticals Inc., of New York, received Swiss regulatory approval to begin its Phase IIa study with oral Oleoyl-estrone for obesity

PeriCor Therapeutics Inc., of New York, said a study of its cardioprotective agent acadesine demonstrated the drug's ability to prolong long-term survival in those patients who suffer heart attacks following heart bypass surgery